Copeptin

From WikiMD's WELLNESSPEDIA

Copeptin is a 39-amino acid glycopeptide derived from the C-terminal part of the precursor of vasopressin, also known as antidiuretic hormone (ADH). It is co-released with vasopressin from the posterior pituitary gland in response to changes in plasma osmolality and blood volume. Copeptin is considered a stable surrogate marker for vasopressin levels in the body.

Structure and Function[edit]

Copeptin is part of the pre-pro-hormone of vasopressin, which is synthesized in the hypothalamus and transported to the posterior pituitary gland. The pre-pro-hormone is cleaved to produce vasopressin, neurophysin II, and copeptin. Copeptin's primary role is to ensure the proper folding and stability of the vasopressin precursor during its synthesis and transport.

Clinical Significance[edit]

Copeptin has emerged as a valuable biomarker in various clinical settings due to its stability and ease of measurement compared to vasopressin. It is used in the diagnosis and prognosis of several conditions, including:

  • Diabetes insipidus: Copeptin levels can help differentiate between central and nephrogenic diabetes insipidus.
  • Heart failure: Elevated copeptin levels are associated with worse outcomes in patients with heart failure.
  • Sepsis: Copeptin can be used as a prognostic marker in septic patients.
  • Acute myocardial infarction: Copeptin, in combination with troponin, improves the early diagnosis of acute myocardial infarction.

Measurement[edit]

Copeptin levels are measured using immunoassays, which are highly sensitive and specific. Blood samples are typically collected, and the plasma or serum is analyzed to determine copeptin concentrations.

Research and Future Directions[edit]

Ongoing research is exploring the potential of copeptin as a biomarker in other diseases and conditions, such as chronic kidney disease, hyponatremia, and stress-related disorders. The development of new assays and technologies may further enhance the clinical utility of copeptin in the future.

See Also[edit]

References[edit]


External Links[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.